The Latest Cardiac and Vascular News
Medtronic sponsors research aimed at improving patient outcomes ADDISON, Texas, May 28, 2020 (GLOBE NEWSWIRE) — Jordan R.H. Hoffman, MD, Assistant Professor in Cardiac Surgery at Vanderbilt University School of Medicine in Nashville, TN., has received the O.H. Frazier Award in MCS Translational Research sponsored by Medtronic and administered by […]
Q4 Revenue of $6.0 Billion Decreased 26% Reported and 25% Organic Q4 GAAP Diluted EPS of $0.48; Q4 Non-GAAP Diluted EPS of $0.58 Financial Results In-Line with Update Provided on April 21 and Consistent with Impact Felt Across MedTech Industry FY20 Cash Flow from Operations of $7.2 Billion; FY20 Free […]
Milestone Results Presented as Late-Breaking Clinical Science at SCAI 2020 DUBLIN, May 15, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced results from two late-breaking clinical trials presented virtually at the 2020 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. Ten-year outcomes from the Melody™ Transcatheter Pulmonary Valve (TPV) Therapy […]
DUBLIN, May 18, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced Jeffrey J. Popma, M.D., professor of medicine at Harvard Medical School and director of interventional cardiology at Beth Israel Deaconess Medical Center in Boston, will join Medtronic as Vice President and Chief Medical Officer […]
ACC.20/WCC: Low Rates of Paravalvular Leak and High Survival Observed in Late-breaking Clinical Trial of Low-Risk Bicuspid Aortic Stenosis Patients DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced late-breaking clinical data from the Low Risk Bicuspid Study assessing the use of the […]
First Study in the U.S. and Japan to Report Results on One-Month DAPT Duration in High Bleeding Risk Patients with Current-Generation DES DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR) […]
ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication Medtronic Receives FDA “Breakthrough Device Designation” for Symplicity Spyral™ Renal Denervation System DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first-ever clinical data from the SPYRAL HTN-OFF MED […]
Revenue of $7.7 Billion Increased 2.3% Reported and 2.6% Organic GAAP Diluted EPS of $1.42 Increased 51%; Non-GAAP Diluted EPS of $1.44 Increased 12% Cash Flow from Operations of $2.4 Billion Increased 17%; Free Cash Flow of $2.1 Billion Increased 21% Company Raises Full Year EPS Guidance DUBLIN, Feb. 18, […]
SPYRAL DYSTAL Study to Evaluate the Effects of RDN Using Fewer, Targeted Ablations to Achieve Meaningful Blood Pressure Reductions DUBLIN, Feb. 04, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced it will begin enrollment in a pilot study evaluating the safety and efficacy of the Symplicity™ Spyral renal denervation (RDN) system […]
Next Generation Technology Includes Features that Automatically Adjust to Patient Needs, and Offers Physicians Heart Failure Diagnostic Insights DUBLIN, Jan. 30, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced it has received CE (Conformité Européenne) Mark for its Cobalt™ and Crome™ portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators […]
